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1

Rehabilitation of Neuromyelitis Optica (Devic’s Syndrome): 3 Case Reports

2

Abstract

3

We describe the inpatient clinical rehabilitation course of three patients with

4

neuromyelitis optica (NMO; Devic’s Syndrome). These patients had varying functional

5

deficits. Each patient improved in several functional independence measures (FIM

6

domains), but had minimal to no progress in other domains after acute rehabilitation stays

7

between 1 to 1.5 months. NMO is a severe central nervous system demyelinating

8

syndrome distinct from MS, characterized by optic neuritis, myelitis, and at least two of

9

three criteria: longitudinally extensive cord lesion, MRI nondiagnostic for multiple

10

sclerosis, or NMO-IgG seropositivity. Persons with NMO may demonstrate improved

11

function with rehabilitation efforts; though gains may be lost to relapse

12

immunomodulatory intervention may augment the benefits of rehabilitation.

Future

13
14
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Text

20
21

Neuromyelitis optica (NMO, Devic Syndrome, Devic’s Syndrome) is a demyelinating

22

disorder distinguished by the combination of optic neuritis (ON) and myelitis. These

23

symptoms can be mischaracterized as multiple sclerosis (MS). NMO has a more acute

24

and severe course. Although NMO is closely associated with MS, it has specific

25

diagnostic criteria, and unique pathological features compared to prototypic MS.1,2,3,4

26
27

History

28

In 1870, Sir Thomas Clifford Allbutt first described an association between myelitis and

29

optic nerve disease.5 The myelitis followed optic nerve changes by approximately 3

30

months. In 1879, Erb reported a 52 year old man who developed recurrent optic neuritis

31

followed by subacute myelitis.6 In 1880, Sequin reported that the associations in the

32

literature, including Erbs’s were accidental.7 In 1882, Dreschfeld performed a pathologic

33

exam in a case of optic neuritis and myelitis, reporting inflammation in both the spinal

34

cord and optic nerves.8 In 1888, Gower's textbook recognizes that they are of a common

35

cause.9 In 1894, Devic and his student Gault reviewed 16 previous cases, as well as

36

another case, for Gault’s doctoral thesis and concluded that optic neuritis and myelitis

37

constituted a distinct clinical entity.10,11 In the early to mid-1900’s Beck and Stansbury

38

reported more cases but were unable to conclude whether this was a distinct entity from

39

acute disseminated encephalomyelitis or MS.12,13

40
41

Classification

4
42

Even recent texts have classified NMO as a variant of MS. In the Far East, NMO was

43

characterized as the optico-spinal variant of MS. MS is characterized by two or more

44

occurrences of central nervous system symptoms and signs separated in time and space.

45

The McDonald criteria represent the currents standards in diagnosis for MS.14 Since the

46

late 1800’s there have been several sets of the diagnostic criteria that have attempted to

47

clarify the controversy of NMO as a distinct entity.9,10,15,16 . The distinction between MS

48

and NMO is necessary, particularly for the relapsing form, because of the significant

49

difference in morbidity and mortality.17 Furthermore drugs useful for MS may not be

50

appropriate for NMO. In 1999, Wingerchuck et al proposed diagnostic criteria with 85%

51

sensitivity and 48 % specificity.18 In 2006, his group revised the criteria to define the

52

syndrome, reporting an impressive 99% sensitivity and 90% specificity. The diagnostic

53

criteria characterize NMO by optic neuritis, myelitis, and at least two of three criteria:

54

longitudinally extensive cord lesion, MRI nondiagnostic for MS, or NMO-IgG

55

seropositivity.4

56
57

Demographics

58

Like MS, NMO predominantly affects women. The median age of onset for NMO is in

59

the late 30’s as compared to the late 20’s for MS. MS most commonly affects people of

60

Northern European/Caucasian ancestry. NMO comprises a relatively greater proportion

61

of a non-Caucasian background. The occurrence of ON or severe myelitis in a non-

62

Caucasian ancestry should increase diagnostic suspicion for NMO.19

63
64

Clinical Course

5
65

Wingerchuk et al. characterized the clinical course as either monophasic or relapsing.18

66

The time course of presentation is usually characteristic for each type. Patients with a

67

monophasic course usually present with rapidly sequential presentation of myelitis and

68

ON within a median of 5 days, while the relapsing course has an extended interval

69

between the presentation of the myelitis and ON with a median of 166 days and

70

occasionally 2 years between initial events.

71
72

The initial presentation of monophasic NMO is more severe but recovery is better.

73

Functionally, the monophasic patients are able to maintain some degree of independence

74

despite moderate visual and motor deficits. The relapsing disease may present with less

75

initial severity and better recovery, but recurrent episodes diminish recovery gains.20 The

76

relapsing course has a poor prognosis with more than half developing severe visual loss

77

and an inability to ambulate without modification within 5 years of the disease onset.

78

Furthermore, the patients are at high risk for high cervical myelitis causing respiratory

79

failure and death.21

80
81

Therapy

82

Acute medical therapeutic recommendations in the literature are beyond the scope of this

83

report.

84

combination with prednisone22 or rituximab23 as a measure to prevent recurrence. Just as

85

the diagnostic criteria continue to be refined, the medical treatments for acute episodes as

86

well as prophylactic therapy are a work in progress. The mainstay of rehabilitative

87

therapy is to prevent complications, treat symptoms, and optimize recovery of function in

In a rehabilitation setting, a patient may be admitted on azathioprine in

6
88

order to reduce disability, handicap and improve well-being. We present three patients

89

stricken with relapsing NMO who under went a comprehensive inpatient rehabilitation

90

program and their functionality at discharge.
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Case Reports

91
92

Case 1

93

A 49 year-old woman initially presented with fatigue and chest discomfort. Five months

94

later, she developed left leg numbness, inability to urinate, bilateral ascending sensory

95

deficits to the level of T6, and unsteadiness with gait. She was diagnosed with MS, and

96

experienced nine episodes of recurring thoracic myelitis over four years. These flares

97

were treated with the standard MS therapies and rehabilitation. She was independent in

98

activities of daily living (ADLs) with modified independent mobility using a rolling

99

walker. After further work-up, she was diagnosed with NMO. Her 10th episode began

100

with neck pain and rapidly progressed to obtundation, flaccid tetraparesis, a C2 sensory

101

level and ventilator dependent respiratory failure. After receiving acute medical therapy,

102

she started to improve.

103
104

On admission to an inpatient rehabilitation facility, physical examination revealed

105

monocular blindness on the left, cognitive impairment, anxiety, and marked global

106

weakness in manual muscle testing with right-side 0-1/5 and left-sided 2-3/5. Absence of

107

sensation to light touch and pinprick was noted from the level of T4. Spasticity was

108

generalized at 1/4 Ashworth scale. She required a foley catheter and bowel program. She

109

exhibited maximum deficits in many areas of function. She was dependent for transfers,

110

feeding, grooming, dressing, bathing, toileting (Table 1). Several barriers in her function

111

were high levels of anxiety accompanied by poor endurance and impaired concentration.

112
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Over a 1.5 month period of inpatient rehabilitation, her cognitive function and anxiety

114

improved, and she was able to focus and make functional gains. Her endurance improved

115

and she was able to actively participate in her program. Her manual muscle testing

116

improved to grades 3+/5 in her right upper limb, 4/5 in her left upper limb, and 1-2/5 in

117

her lower limbs. Sensation was intact to the level of T4 dermatome with partial

118

preservation to T10. Spasticity was 1/4 in the upper limbs and 2/4 in the lower limbs.

119

Cystometrogram (CMG) revealed an insensate dyssynergic hyperreflexic bladder that

120

requires a constant foley catheter. She was continent with a bowel program. Functional

121

gains were made in feeding, grooming, and upper extremity dressing. Many areas such

122

as lower extremity dressing, toileting, and transferring had minimal improvement (Table

123

1). She was discharged home with plans for outpatient rehabilitation.

124
125

Case 2

126

A 43 year-old woman was initially diagnosed with multiple sclerosis then shortly

127

afterwards developed right eye blindness. Functionally, she was independent in ADLs

128

and required a cane for modified independent mobility. Two years later, she developed

129

lower extremity weakness with an inability to urinate which was later complicated by

130

urosepsis. Neurologic work-up concluded that she had NMO.

131
132

On admission to our inpatient rehabilitation facility, physical examination revealed a

133

female patient blind in the right eye with impaired vision in left eye. Her upper extremity

134

strength was 4/5 and lower extremity 0/5. Sensation was decreased to light touch and

135

pinprick, without a clear sensory level. She had flaccid paraplegia and bilateral ankle

9
136

contractures. She required a foley catheter and bowel program. She exhibited deficits in

137

many areas of function. Specifically, she was dependent in lower extremity dressing,

138

toileting, bathing, and toilet/tub transfers (Table 1).

139
140

Her flaccid paraplegia persisted after one month of rehabilitation. CMG revealed an

141

areflexic neurogenic bladder with some preservation of bladder sensation, which she

142

managed by intermittent catheterization. She also required a bowel program. Functional

143

gains were made in lower extremity dressing, bathing, and toilet transfers. Areas such as

144

toileting and tub transfers had minimal improvement (Table 1). She was discharged to a

145

skilled nursing facility.

146
147

Case 3

148

A 41 year-old women initially developed transient bilateral blindness, with left eye vision

149

return. Two years later, she developed chest discomfort accompanied by loss of

150

sensation and movement below the level of T3. Extensive work-up revealed cervical and

151

thoracic myelitis and she eventually was diagnosed with NMO. Prior to the presentation

152

of weakness, she was independent in ADLs and ambulation.

153
154

On admission our inpatient rehabilitation facility, physical examination revealed a female

155

patient blind in the right eye. Her upper extremity strength was graded 4/5 and lower

156

extremity 0/5. Sensation was decreased to light touch and pinprick below the level of C6

157

with dysesthesias in her right upper extremity. She had flaccid paraplegia. She required

158

a foley catheter and bowel program. She exhibited deficits in many areas of function.

10
159

Specifically, she was dependent in bathing, lower extremity dressing and toilet/tub

160

transfers (Table 1).

161
162

Her course of rehabilitation was complicated by urosepsis and pulmonary embolism.

163

Eventually, she was able to complete 1 month of uninterrupted rehabilitation. Her

164

physical exam revealed persistent paraplegia with right upper extremity weakness and

165

dysesthesia. CMG revealed an areflexic neurogenic bladder without detrusor contraction

166

or sensation. She required a foley catheter and bowel program. Functional gains were

167

made in feeding, lower extremity dressing, and bathing. Areas such as toileting and tub

168

transfers had no improvement (Table 1). She was discharged home.

169
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Discussion

171

NMO is a severe central nervous system demyelinating syndrome distinct from MS;

172

characterized by optic neuritis, myelitis, and at least two of three criteria: longitudinally

173

extensive cord lesion, MRI nondiagnostic for MS, or NMO-IgG seropositivity. Literature

174

search reveals that NMO is poorly described in the physiatric literature. This is most

175

likely due to the low incidence and prevalence as well as an evolving understanding of

176

the clinicopathological features that set it apart from MS.

177
178

There are a myriad of symptoms and signs of NMO, which must be addressed in a

179

rehabilitation setting to maximize functional recovery. Fatigue can be treated with a

180

planned regiment of rest between therapies, focused energy efficient compensatory

181

strategies, and psychostimulant medications. Spasticity can be treated with frequent

182

stretching of spastic muscles. Incorporation of spasmolytic medications with close

183

monitoring for enhancement of function versus hindering function may assist in overall

184

functional improvement. Other useful modalities are localized nonsystemic blocks and

185

baclofen pumps. Weakness may improve with progressive resistance exercises which

186

may improve function. Care must be taken not to overfatigue the muscles. Neurogenic

187

bladder must also be addressed to prevent long term complications of infection,

188

hydronephrosis, stone formal, vesicouretal reflux, and renal failure. CMG can establish

189

the presence of sphincter dyssyngergia, detrusor hyperreflexia, or detrusor areflexia.

190

Depending upon the severity of the bladder dysfunction, the patient’s mental status and

191

upper limb dexterity, medications, indwelling catheterization or intermittent

192

catheterization may be implemented in an acute rehabilitation setting. Anxiety and

12
193

depression are common. The utilization of a psychologist, group meetings and

194

medications can help make the patient a more active participant in a program.

195

Interventions for memory impairments include the use of a memory books (which must

196

be appropriate for the patient’s visual deficits and possible loss of hand dexterity), a

197

structured environment, and consideration of medications such as donezepil.

198
199

Physiatrists need to focus on optimizing acute rehabilitation in order to treat symptoms,

200

minimize complications and improve the quality of life. This is even more pertinent

201

with NMO versus MS because of the severe sequalae that occur after an acute episode.

202

Rehabilitation planning must consider the progressive nature of the disease and risk of

203

relapse. Kraft says, “…We need to adapt rehabilitation strategies to a progressive

204

neurologic disease with an uncertain course.24” Although he was referring to MS, this

205

concept applies to NMO as well.

206
207

Each of these three patients was not able to return to baseline ADL and ambulatory

208

function after relapse. However, they were able to improve in several domains of

209

function from their initial assessment on admission to a rehabilitation facility. Our first

210

patient was significantly hindered by cognitive impairment, anxiety and fatigue, which

211

improved during her stay. Consequently, she was able to improve her function and had

212

less apprehension when she returned to the community. Our second patient was admitted

213

with a much stronger functional profile and was able to become much less dependent

214

after her rehabilitation. Our third patient provides an example of how medical

215

complications, just as with MS, spinal cord injury, stroke, and traumatic brain injury, can

13
216

interrupt rehabilitation. The patient and her rehabilitation team persevered so that her

217

quality of life was improved. In turn, the period between discharge and her next relapse,

218

she will have improved function.

219
220

All three patients benefited from acute rehabilitation. Although they did not return to

221

prior functional levels, they were able to improve. Functional gains can be expected, with

222

attention to treating symptoms and preventing complications, through a comprehensive

223

rehabilitation program.

224
225

Conclusion

226

Although rehabilitation strategies for MS are well reported in the literature, those for

227

NMO are not. This may be due to a historical confounding of rehabilitation modalities for

228

NMO with MS. The neurological literature now shows that there are unique clinical

229

characteristics22, 23, 25 and pathological processes that distinguish MS from NMO. These

230

differences may affect the neurological therapy and acute management of the disease.

231

Thus, as newer treatments become available, it will be necessary to modify and optimize

232

rehabilitation strategies to treat symptoms and prevent complications to maximize

233

recovery of function. Just as controlled clinical trials will need to be developed to

234

identify the best acute care neurological treatments; controlled trials will need to be

235

developed to assess recovery of function in the acute care and long term rehabilitation

236

settings. In order to do this we will need to determine the best set of outcomes measures

237

for comparison of inpatient rehabilitation treatments. As documented in our patient

238

series, functional gains can be made by a comprehensive rehabilitation program.
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